Bonizol5 mg/100 ml

Bonizol 5 mg/100 ml is a nitrogen-containing bisphosphonate given by intravenous (IV) infusion, indicated for the following osteoporosis-related uses:

Established / Approved Uses

• Treatment of postmenopausal osteoporosis — reduces the incidence of vertebral, hip, and non-vertebral fractures.
• Prevention of postmenopausal osteoporosis in women at risk of bone loss.
• Treatment to increase bone mass in men with osteoporosis.
• Treatment and prevention of glucocorticoid-induced osteoporosis in men and women expected to remain on long-term systemic corticosteroid therapy (≥7.5 mg/day prednisone equivalent for ≥12 months).

Important Note

This entry covers the lower-dose, infrequent (annual or less often) infusion regimen used specifically for osteoporosis. It is distinct from the higher-dose, more frequent regimen of the same molecule used for hypercalcemia of malignancy or bone metastases, which is not covered by this entry.

Each formulation of Bonizol 5 mg/100 ml typically contains zoledronic acid equivalent to 5 mg zoledronic acid (anhydrous) in a ready-to-use 100 mL intravenous infusion solution, along with mannitol and sodium citrate as excipients.

Bonizol 5 mg/100 ml is a potent, nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption. Unlike oral bisphosphonates that require daily or weekly dosing, this formulation is given as an infrequent intravenous infusion (as seldom as once yearly for osteoporosis treatment, or once every two years for prevention), which improves adherence in patients who have difficulty with oral bisphosphonate regimens or gastrointestinal tolerability.

It works by binding to bone mineral and suppressing the activity of osteoclasts, the cells responsible for breaking down bone tissue, thereby increasing bone mineral density and reducing fracture risk over time.

Bonizol 5 mg/100 ml belongs to the nitrogen-containing bisphosphonate class of drugs, a subgroup of bone-resorption inhibitors (anti-resorptive agents) used in the management of metabolic bone diseases.

Bonizol 5 mg/100 ml acts primarily on bone tissue. It binds with high affinity to hydroxyapatite in bone mineral, particularly at sites of active bone remodeling.

Mechanism: It inhibits farnesyl pyrophosphate synthase, a key enzyme in the mevalonate (HMG-CoA reductase) pathway within osteoclasts. This disrupts prenylation of small GTP-binding proteins essential for osteoclast cytoskeletal integrity and function, leading to osteoclast inactivation and apoptosis. The net effect is suppression of bone resorption, which allows osteoblastic (bone-forming) activity to outpace resorption, resulting in a net gain in bone mineral density.

Pharmacokinetics: Following IV infusion, plasma concentrations decline rapidly; the drug is taken up extensively by bone tissue, where it can remain bound for months to years, with the remainder eliminated largely unchanged by the kidneys. It is not significantly metabolized.

Bonizol 5 mg/100 ml must be administered by a healthcare professional as a single IV infusion lasting at least 15 minutes, through a vented infusion line. Patients should be adequately hydrated beforehand, and renal function should be checked prior to each infusion. Do not administer as an IV push or bolus injection. See Dosage and Administration for complete pre-infusion requirements.

The following interactions with Bonizol 5 mg/100 ml are clinically significant:

• Aminoglycosides: Concomitant use may have an additive effect leading to lower serum calcium levels for longer than usually expected; monitor calcium closely.
• Loop diuretics: May increase the risk of hypocalcemia when used with Bonizol 5 mg/100 ml.
• Nephrotoxic drugs (e.g. NSAIDs, other nephrotoxic agents): Concurrent use should be undertaken with caution due to additive risk of renal impairment.
• Other bisphosphonates or calcitonin: Concomitant use is not recommended due to potential additive hypocalcemic effects.
• Thalidomide-based regimens (e.g. in myeloma patients on other bisphosphonate uses): May increase renal toxicity risk; not directly relevant to standard osteoporosis dosing but noted for completeness in patients on multiple nephrotoxic agents.

Inform your physician about all medicines, supplements, and calcium/vitamin D products being taken before receiving Bonizol 5 mg/100 ml.

Common side effects of Bonizol 5 mg/100 ml are usually related to the acute phase reaction following the first infusion and generally decrease with subsequent doses.

Very Common / Common

• Flu-like symptoms: fever, myalgia (muscle aches), arthralgia (joint pain), fatigue
• Headache
• Nausea, vomiting, diarrhea, abdominal pain
• Bone pain
• Injection/infusion-site reactions
• Mild, transient hypocalcemia

Less Common but Important

• Atrial fibrillation (reported in some studies; causal link not firmly established)
• Renal function abnormalities
• Osteonecrosis of the jaw (rare; see Precautions)
• Atypical femur fractures with long-term use (rare; see Precautions)
• Severe hypocalcemia (uncommon, more likely with untreated vitamin D deficiency or renal impairment)
• Uveitis, scleritis, or other ocular inflammation (rare)

Report any severe or persistent symptoms, especially jaw pain/swelling, unusual thigh/groin pain, or muscle cramps/tingling (signs of hypocalcemia), to your physician promptly.

Pregnancy: Bonizol 5 mg/100 ml is not recommended for use during pregnancy. Animal studies have shown reproductive toxicity, and there is limited human data. Women of childbearing potential should have pregnancy excluded before treatment and should be advised to avoid becoming pregnant during and for a period after treatment, given the drug's long retention in bone. Bonizol 5 mg/100 ml should be used in pregnancy only if clearly needed and only after the physician has weighed potential benefit against potential risk to the fetus; if pregnancy occurs, therapy should be discontinued and the physician informed immediately.

Lactation: It is not known whether Bonizol 5 mg/100 ml is excreted in human breast milk. Because of the potential for serious adverse effects in a nursing infant and the drug's prolonged skeletal retention, a decision should be made, in consultation with a physician, whether to discontinue breastfeeding or to avoid/discontinue the drug, taking into account the importance of treatment to the mother.

The following precautions apply to treatment with Bonizol 5 mg/100 ml:

Osteonecrosis of the Jaw (ONJ)

Rare cases of ONJ have been reported, more often in patients with cancer receiving much higher/more frequent bisphosphonate doses, but also reported with osteoporosis dosing. Risk factors include invasive dental procedures, poor oral hygiene, and concomitant corticosteroid or chemotherapy use. A dental examination with completion of any necessary invasive dental work is recommended before starting therapy in at-risk patients. Patients should maintain good oral hygiene and inform their dentist that they are receiving this treatment.

Atypical Femur Fractures

Atypical, low-trauma subtrochanteric and femoral shaft fractures have been reported with long-term bisphosphonate use. Patients presenting with new thigh, hip, or groin pain during treatment should be evaluated for possible incomplete femur fracture.

Acute Phase Reaction

Flu-like symptoms (fever, myalgia, arthralgia, headache) may occur within 3 days after the first infusion and typically resolve within a few days; this reaction is generally milder or absent with subsequent infusions. Antipyretics (e.g. paracetamol) may help relieve symptoms.

Renal Function

Renal function must be assessed before each dose. Adequate hydration before and during infusion is required to reduce the risk of renal toxicity. Use with caution alongside other nephrotoxic drugs.

Hypocalcemia

Must be corrected before starting treatment; ensure adequate calcium and vitamin D intake throughout treatment (see Contraindications and Dosage and Administration).

Musculoskeletal Pain

Severe, occasionally disabling bone, joint, or muscle pain has been reported; onset may range from a day to several months after starting treatment.

Overdosage with Bonizol 5 mg/100 ml may result in clinically significant hypocalcemia, hypophosphatemia, and hypomagnesemia, and may impair renal function further. If overdose is suspected, seek immediate medical attention or contact emergency services / a poison control center right away. Management is supportive and should be carried out under close medical supervision (e.g. correction of calcium, phosphorus, and magnesium levels, and monitoring of renal function), in a hospital setting. Do not attempt to manage a suspected overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Do not freeze. Keep out of reach of children. Use immediately after opening; discard any unused portion.

Elderly

No overall differences in safety or efficacy have been observed compared to younger patients, but caution is warranted given the higher likelihood of decreased renal function; renal function should be assessed before each dose of Bonizol 5 mg/100 ml.

Renal Impairment

No dosage adjustment is required for creatinine clearance ≥35 mL/min. Bonizol 5 mg/100 ml is contraindicated in patients with creatinine clearance below 35 mL/min or acute renal impairment (see Contraindications).

Hepatic Impairment

No dosage adjustment is considered necessary, as the drug is not metabolized by the liver; however, no formal studies have been conducted in patients with hepatic impairment.

Pediatric Use

Safety and efficacy have not been established in pediatric patients; Bonizol 5 mg/100 ml is not indicated for use in children (see Pediatric Uses).

The optimal duration of treatment with Bonizol 5 mg/100 ml for osteoporosis has not been definitively established. Many patients are treated for 3 years (as studied in pivotal trials), after which the physician may reassess fracture risk to decide whether to continue annual dosing, extend the interval, or consider a "drug holiday." Treatment duration and re-evaluation intervals should always be individualized by the treating physician based on ongoing fracture risk.

Bisphosphonates (nitrogen-containing); Bone resorption inhibitors / anti-resorptive agents

Bonizol 5 mg/100 ml inhibits farnesyl pyrophosphate synthase in the osteoclast mevalonate pathway, disrupting osteoclast function and survival, thereby suppressing bone resorption and allowing bone mineral density to increase over time. See Pharmacology for full mechanistic detail.

The safety and efficacy of Bonizol 5 mg/100 ml in pediatric patients (below 18 years of age) have not been established. It is not indicated for use in children and should not be administered to this population outside of specialist clinical settings for specific bone disorders unrelated to this entry's approved osteoporosis indications.